Search Results

Derm-Biome Pharmaceuticals, Inc is pleased to announce that, in partnership with TransBIOtech, is being awarded an Applied Research and Development grant via the College and Community Innovation program administered through the Natural Sciences and Engineering Council of Canada in collaboration with the Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research.

Brain Cancer Canada is excited to announce the issuance of an $80,000 grant to support groundbreaking research by Dr. Sujoy Banik and his team at Lawson Health Research Institute in London, Ontario, Canada.

Charles River Laboratories International, Inc. announced a multidisciplinary program, funded through a $1.3 million grant from the Foundation for Chemistry Research & Initiatives, in coordination with the American Chemistry Council’s Long-Range Research Initiative, to develop a New Approach Methodology inhalation toxicology test to reduce reliance on traditional animal research methods.

In Texas, the Plano City Council approved a development agreement that supports a planned project that would bring over 3 million square feet of life sciences space to the area.

Qu Biologics Inc. is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering.

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics has been granted NOK 16 million by the Research Council of Norway.

ONK Therapeutics (“ONK”) and NAYA Biosciences Inc. (“NAYA”) today announced that they have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK™ bispecific antibodies.